MARKET

TCON

TCON

TRACON Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.810
-0.050
-1.03%
Closed 18:58 09/25 EDT
OPEN
5.22
PREV CLOSE
4.860
HIGH
5.32
LOW
4.720
VOLUME
940.28K
TURNOVER
--
52 WEEK HIGH
6.37
52 WEEK LOW
0.9500
MARKET CAP
63.41M
P/E (TTM)
-1.0794
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
TRACON highlights updated envafolimab clinical results in MSI-H/dMMR colorectal cancer
TRACON Pharmaceuticals ([[TCON]] -13.3%) highlighted updated clinical data from the pivotal trial of envafolimab in MSI-H/dMMR cancer patients that were presented by the corporate partners, 3D Medicines and Alphamab Oncology.
Seekingalpha · 6d ago
TRACON Pharmaceuticals Highlights Updated Envafolimab Clinical Results in MSI-H/dMMR Colorectal Cancer
TRACON’s Pivotal ENVASARC Trial of envafolimab in the Sarcoma Subtypes of UPS and MFS Expected to Initiate Dosing in 4Q 2020SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of
GlobeNewswire · 6d ago
The Daily Biotech Pulse: Roche's COVID Combo Therapy Reduces Need For Ventilation, ESMO Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 17)
Benzinga · 09/18 11:30
MRSN, FSLR among premarket losers
Strongbridge Biopharma (SBBP) -16% after pricing $25M share offering.NuCana (NCNA) -16% after pricing secondary offering.Dave & Buster's Entertainment (PLAY) -13%.Xenetic Biosciences (XBIO) -9%.Mersana Therapeutics (MRSN) -8% after reporting XMT-1536 data in ovarian cancer cohort.Inovio Pharmaceuticals (INO)
Seekingalpha · 09/17 12:17
TRACON Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
SAN DIEGO, Sept. 10, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner
GlobeNewswire · 09/10 13:05
Fulgent Genetics leads healthcare gainers; Akebia Therapeutics and NanoViricides among losers
Gainers: Fulgent Genetics (FLGT) +20%. TRACON Pharmaceuticals (TCON) +17%. Applied Genetic Technologies (AGTC) +12%. CNS Pharmaceuticals (CNSP) +11%. Sutro Biopharma (STRO) +11%.Losers: Akebia Therapeutics (AKBA) -72%. T2 Biosystems (TTOO) -13%.Adaptive Biotechnologies (ADPT) -11%. NanoViricides (NNVC) -11%. Baudax Bio
Seekingalpha · 09/03 15:04
TRACON Pharmaceuticals to Present at the Wells Fargo Virtual Healthcare Conference
SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner
GlobeNewswire · 09/03 13:05
Jounce Therapeutics rallies on license deal with Gilead, Tracon Pharma follows, I-Mab, Kindred Biosciences among major losers
Gainers: Jounce Therapeutics (JNCE) +42%, TRACON Pharmaceuticals (TCON) +13.8%, Nano-X Imaging (NNOX) +13.6%, Athenex (ATNX) +11.5%, Surface Oncology (SURF) +8%.Losers: I-Mab (IMAB) -14.5%, Kindred Biosciences (KIN) -13.7%, ProQR Therapeutics (PRQR) -13%, Vaxart (VXRT) -12.9%, ADiTx Therapeutics (ADTX) -12.2%.
Seekingalpha · 09/01 14:57
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TCON. Analyze the recent business situations of TRACON Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TCON stock price target is 5.33 with a high estimate of 7.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 33
Institutional Holdings: 2.02M
% Owned: 15.36%
Shares Outstanding: 13.18M
TypeInstitutionsShares
Increased
8
259.82K
New
6
36.12K
Decreased
1
8.26K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/President/Chief Executive Officer/Chief Financial Officer/Director
Charles Theuer
Executive Vice President
Bonne Adams
Other
H Logan
Executive Vice President
Sharon Real
Chief Accounting Officer
Scott Brown
Other
Mark Wiggins
Director
Saundra Pelletier
Independent Director
William LaRue
Independent Director
Martin Mattingly
Independent Director
J. Rainer Twiford
Independent Director
Stephen Worland
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About TCON
TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company's research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company's lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of TRACON Pharmaceuticals Inc stock information, including NASDAQ:TCON real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TCON stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TCON stock methods without spending real money on the virtual paper trading platform.